Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of ...
The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human ...
Organizations plan to accelerate development of models for biology and chemistry. Recursion, a TechBio company, revealed a collaboration with NVIDIA to fast-track development of its artificial ...
Nvidia (NVDA), the Silicon Valley-based microprocessing giant with a growing presence in the life sciences, has spent the first three weeks of this year continuing its climb into the Wall Street ...
Operational complementarities expected to yield annual synergies of approximately $100 million ...
Oxford-based pharmaceutical firm Exscientia has agreed to an acquisition by Recursion, a biotech from Utah, US, in a transaction worth $688 million. The deal comes as major firms look to AI – as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results